Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Total Liabilities: 2020-2025

Historic Total Liabilities for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to $212.9 million.

  • Arcutis Biotherapeutics' Total Liabilities fell 24.16% to $212.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $212.9 million, marking a year-over-year decrease of 24.16%. This contributed to the annual value of $191.3 million for FY2024, which is 24.28% down from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Total Liabilities of $212.9 million as of Q3 2025, which was down 0.26% from $213.5 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Total Liabilities registered a high of $280.7 million during Q3 2024, and its lowest value of $18.4 million during Q2 2021.
  • Over the past 3 years, Arcutis Biotherapeutics' median Total Liabilities value was $240.2 million (recorded in 2023), while the average stood at $235.5 million.
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Total Liabilities soared by 891.71% in 2022, and later decreased by 24.28% in 2024.
  • Over the past 5 years, Arcutis Biotherapeutics' Total Liabilities (Quarterly) stood at $110.5 million in 2021, then surged by 116.97% to $239.7 million in 2022, then rose by 5.43% to $252.7 million in 2023, then declined by 24.28% to $191.3 million in 2024, then declined by 24.16% to $212.9 million in 2025.
  • Its last three reported values are $212.9 million in Q3 2025, $213.5 million for Q2 2025, and $201.4 million during Q1 2025.